Mebanazine

Summary

Mebanazine (CHEMBL1909283) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 136.19 Da · C8H12N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1909283
Name	Mebanazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6179
Molecular formula	C8H12N2
Molecular weight	136.19
InChIKey	HHRZAEJMHSGZNP-UHFFFAOYSA-N

SMILES: CC(C1=CC=CC=C1)NN

IUPAC name: 1-phenylethylhydrazine

Also known as: Actamol, Mebanazina, Mebanazine, mebanazine, MEBENAZINE, MEBANAZINE

Parent form; salt/anhydrous children: CHEMBL3186515

Patent coverage: 716 distinct patent families (1,314 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).